You need to enable JavaScript to run this app.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
AML Types
Signaling pathway mutations
Epigenetic modifier mutations
Origin
Chromosomal aberrations
Nucleophosmin mutations
Tumor suppressor mutations
Spliceosome mutations
Transcription factor mutations
Cohesin mutations
View all Types
Uwe Platzbecker
Scientific Advisory Board Member
Uwe Platzbecker
Scientific Advisory Board Member
Types
FLT3-ITD
FLT3-TKD
IDH1
IDH2
NPM1
Promyelocytic leukemia
Spliceosome mutations
TET2
TP53
Interventions
ABBV-621
Allo-HSCT
AMG 330
AMV564
Arsenic trioxide
ATRA
Azacitidine
CAR T-cell therapy
CC-486
Cytarabine
Decitabine
Enasidenib
Gemtuzumab ozogamicin
Gilteritinib
H3B-8800
IMGN632
Ivosidenib
Magrolimab
Midostaurin
Pembrolizumab
Quizartinib
Ruxolitinib
Selinexor
Sorafenib
Sunitinib
Tacrolimus
Talacotuzumab
Tandutinib
Venetoclax
Events
ASH 2016
ASH 2017
ASH 2019
ASH 2020
EBMT 2019
EHA 2018
EHA 2019
ISAL 2019
SOHO 2020
Trials
ADMIRAL
AMADEUS
AML1310
AMLSG 09-09
AMV564-101
Beat AML
E2906
HOVON 97
MORPHO
QoLESS-AZA-AMLE
QuANTUM-R
QUAZAR AML-001
RATIFY
RELAZA2
SAIL
SAMBA
SIERRA
SORMAIN
VIOLA
All
|
5 Articles
|
13 Videos
|
0 Podcasts